VIRALEZE is registered in more than 30 countries, including in Europe, the UK, Middle East, and Asia
Australia-based Starpharma has announced that SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95% and 99.7% reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays. Industrial Hpmc
The virucidal assays conducted at the Scripps Research Institute in the US assessed the irreversible nature of the effect of a compound against viruses.
In addition to testing the virucidal activity of SPL7013, the Scripps testing assessed the activity of two antiviral agents used in widely available nasal sprays - hydroxypropyl methyl cellulose (HPMC) and iota-carrageenan. In contrast to the potent and rapid effect of SPL7013, HPMC and iota-carrageenan did not exhibit virucidal effect in this experiment, even after 30 minutes.
The antiviral activity of SPL7013 in other pandemic-causing influenza A viruses has previously been reported by Starpharma, with SPL7013 demonstrating potent antiviral activity against H1N1 (Swine Flu) and H3N2 (Avian Flu).
These new virucidal findings are consistent with the previously reported activity of SPL7013 against multiple variants of SARS-CoV-2, including Delta, Alpha, Beta, Gamma, and Omicron, as well as other respiratory viruses that cause the common cold. The broad-spectrum antiviral and virucidal activity of SPL7013 (VIRALEZE), which encompasses all of the pandemic-causing respiratory viruses, highlights the opportunities for VIRALEZE in combatting seasonal flu epidemics as well as pandemic preparedness.
“APAC continues to be a glo...
"There's strong commercial ...
"Diagnostic market in the A...
Elevating Life science industry sta
VALUE is the Trending Word of 2023
Singapore's A*STAR & BD to advance
New funding by NZ to boost RNA rese
Takeda to invest ¥100 B in new faci
Hong Kong develops approach to esti
CPHI Pharma Awards open to global i
Has Asia-Pacific region made progress towards malaria elimination?
1 North Bridge Road, #08-08 High Street Centre, Singapore 179094 Email : communications@biospectrumasia.com +65 90150305
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Rdp Manufacturing Web Interface Conceived and Powered By : SCI Knowledge Interlinks